These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 22933168

  • 1. Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.
    Polyzos SA, Anastasilakis AD, Anagnostis P, Kita M, Arsos G, Moralidis E, Papatheodorou A, Terpos E.
    Endokrynol Pol; 2012; 63(4):312-5. PubMed ID: 22933168
    [Abstract] [Full Text] [Related]

  • 2. The use of zoledronic acid for Paget's disease of bone.
    Maricic M.
    Curr Osteoporos Rep; 2006 Mar; 4(1):40-4. PubMed ID: 16527007
    [Abstract] [Full Text] [Related]

  • 3. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A.
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [Abstract] [Full Text] [Related]

  • 4. Zoledronic acid for Paget's disease of bone.
    Maricic M.
    Drugs Today (Barc); 2007 Dec; 43(12):879-85. PubMed ID: 18174973
    [Abstract] [Full Text] [Related]

  • 5. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.
    Keating GM, Scott LJ.
    Drugs; 2007 Dec; 67(5):793-804. PubMed ID: 17385948
    [Abstract] [Full Text] [Related]

  • 6. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.
    Al Nofal AA, Altayar O, BenKhadra K, Qasim Agha OQ, Asi N, Nabhan M, Prokop LJ, Tebben P, Murad MH.
    Osteoporos Int; 2015 Jul; 26(7):1875-91. PubMed ID: 26037791
    [Abstract] [Full Text] [Related]

  • 7. Persistent effect of zoledronic acid in Paget's disease.
    Tziomalos K, Florentin M, Krikis N, Perifanis V, Karagiannis A, Harsoulis F.
    Clin Exp Rheumatol; 2007 Jul; 25(3):464-6. PubMed ID: 17631747
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Diagnosis and treatment of Paget's disease of bone: a mini-review.
    Ferraz-de-Souza B, Correa PH.
    Arq Bras Endocrinol Metabol; 2013 Nov; 57(8):577-82. PubMed ID: 24343625
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological therapy of Paget's and other metabolic bone diseases.
    Hosking D.
    Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
    [Abstract] [Full Text] [Related]

  • 11. Zoledronic acid for treatment of Paget's disease of bone.
    Devogelaer JP, Manicourt DH.
    Expert Opin Pharmacother; 2007 Nov; 8(16):2863-9. PubMed ID: 17956205
    [Abstract] [Full Text] [Related]

  • 12. Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid.
    Devogelaer JP, Geusens P, Daci E, Gielen E, Denhaerynck K, Macdonald K, Hermans C, Vancayzeele S, Abraham I, Boonen S.
    Calcif Tissue Int; 2014 Mar; 94(3):311-8. PubMed ID: 24271562
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of Paget's disease of bone: importance of the zoledronic acid].
    Griz L, Colares V, Bandeira F.
    Arq Bras Endocrinol Metabol; 2006 Oct; 50(5):845-51. PubMed ID: 17160207
    [Abstract] [Full Text] [Related]

  • 14. Diagnosis and treatment of Paget's disease of bone : A clinical practice guideline.
    Muschitz C, Feichtinger X, Haschka J, Kocijan R.
    Wien Med Wochenschr; 2017 Feb; 167(1-2):18-24. PubMed ID: 27600563
    [Abstract] [Full Text] [Related]

  • 15. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR.
    J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
    [Abstract] [Full Text] [Related]

  • 16. Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone.
    Reid IR, Maslowski K.
    Calcif Tissue Int; 2017 Jul; 101(1):43-49. PubMed ID: 28324123
    [Abstract] [Full Text] [Related]

  • 17. Drug treatment strategies for paget's disease: relieving pain and preventing progression.
    Merlotti D, Rendina D, Cavati G, Abate V, Falchetti A, Mingiano C, Nuti R, Gennari L.
    Expert Opin Pharmacother; 2023 Apr; 24(6):715-727. PubMed ID: 36961938
    [Abstract] [Full Text] [Related]

  • 18. Medical management of Paget's disease of bone: indications for treatment and review of current therapies.
    Siris ES, Lyles KW, Singer FR, Meunier PJ.
    J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018
    [Abstract] [Full Text] [Related]

  • 19. Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget's disease of bone.
    Polyzos SA.
    Clin Rheumatol; 2011 Jan; 30(1):149-50. PubMed ID: 21053036
    [No Abstract] [Full Text] [Related]

  • 20. [Zoledronic acid efficacy in Paget's disease of bone: a three-year experience].
    Conesa Mateos A, Rotés Sala D, Almirall Bernabé M, Carbonell Abelló J.
    Med Clin (Barc); 2006 Oct 28; 127(16):635-6. PubMed ID: 17145033
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.